Effectiveness of interferon α in mycosis fungoides therapy

被引：0

作者：

Sikorska, Monika ^{[1
]}

Sokolowska-Wojdylo, Malgorzata ^{[1
]}

Kowalczyk, Anna ^{[2
]}

Roszkiewicz, Jadwiga ^{[1
]}

机构：

[1] Med Univ Gdansk, Dept Dermatol Venereol & Allergol, PL-80210 Gdansk, Poland

[2] Med Univ Gdansk, Dept Oncol & Radiotherapy, PL-80210 Gdansk, Poland

来源：

POSTEPY DERMATOLOGII I ALERGOLOGII | 2012年 / 29卷 / 01期

关键词：

interferon-alpha; 2a; mycosis fungoides; PUVA; UVB311; T-CELL LYMPHOMA; SEZARY-SYNDROME; CLINICAL-TRIAL; PUVA; STAGE; PHOTOTHERAPY; COMBINATION; EXPERIENCE; RADIATION; SURVIVAL;

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma. Skin manifestations are generally the first signs of the disease. Many topical and systemic therapeutic alternatives are utilized in MF treatment, but there is no defined curative treatment regimen. One of the successful agents is interferon-alpha (IFN-alpha), which shows appreciable responses, especially in combination therapy with psoralen and ultraviolet A (PUVA). However, the optimal IFN dose, schedule, and duration of therapy are still not determined. We describe 2 patients suffering from ME, being treated at the Clinic of Dermatology, Venereology and Allergology in Gdansk, including IFN and phototherapy with very satisfactory results.

引用

页码：51 / 55

页数：5

共 33 条

[1] Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal [J].

Agar, Nita Sally ;

Wedgeworth, Emma ;

Crichton, Siobhan ;

Mitchell, Tracey J. ;

Cox, Michael ;

Ferreira, Silvia ;

Robson, Alistair ;

Calonje, Eduardo ;

Stefanato, Catherine M. ;

Wain, Elizabeth Mary ;

Wilkins, Bridget ;

Fields, Paul A. ;

Dean, Alan ;

Webb, Katherine ;

Scarisbrick, Julia ;

Morris, Stephen ;

Whittaker, Sean J. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4730-4739

[2]

ANGIOLI R, 1993, CANCER, V71, P3717, DOI 10.1002/1097-0142(19930601)71:11<3717::AID-CNCR2820711140>3.0.CO

[3]

2-I

[4] THE INTERFERONS - MECHANISMS OF ACTION AND CLINICAL-APPLICATIONS [J].

BARON, S ;

TYRING, SK ;

FLEISCHMANN, WR ;

COPPENHAVER, DH ;

NIESEL, DW ;

KLIMPEL, GR ;

STANTON, GJ ;

HUGHES, TK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (10) :1375-1383

[5] RECOMBINANT LEUKOCYTE A-INTERFERON - AN ACTIVE AGENT IN ADVANCED CUTANEOUS T-CELL LYMPHOMAS [J].

BUNN, PA ;

FOON, KA ;

IHDE, DC ;

LONGO, DL ;

EDDY, J ;

WINKLER, CF ;

VEACH, SR ;

ZEFFREN, J ;

SHERWIN, S ;

OLDHAM, R .

ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) :484-487

[6]

BUNN PA, 1986, CANCER, V57, P1689, DOI 10.1002/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO

[7]

2-M

[8] SYSTEMIC THERAPY OF CUTANEOUS T-CELL LYMPHOMAS (MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME) [J].

BUNN, PA ;

HOFFMAN, SJ ;

NORRIS, D ;

GOLITZ, LE ;

AELING, JL .

ANNALS OF INTERNAL MEDICINE, 1994, 121 (08) :592-602

[9]

Chiarion-Sileni V, 2002, CANCER-AM CANCER SOC, V95, P569, DOI 10.1002/cncr.10706

[10]

Duvic M, 2001, ARCH DERMATOL, V137, P581

← 1 2 3 4 →